Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amarin completes dosing in fixed-dose Vascepa/statin study

Dec. 18, 2012

FDA approves Novartis' Signifor for treatment of Cushing's disease

Dec. 17, 2012

EMA committee adopts negative opinion on MAA for Kynamro in HoFH

Dec. 17, 2012

Roche presents novel hormone-sensitive lipase inhibitors

Dec. 17, 2012

FDA accepts NDA for Pfizer and Ligand's BZA/CE

Dec. 17, 2012

Japanese scientists present novel agents for Fabry's disease

Dec. 14, 2012

Lamazym advances to phase III alpha-mannosidosis trial

Dec. 14, 2012

Janssen submits NDA for canagliflozin/metformin combination

Dec. 14, 2012

Novel GR antagonists discovered to prevent antipsychotic-induced weight gain

Dec. 13, 2012

uniQure begins phase I study in acute intermittent porphyria

Dec. 13, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...